{
    "ticker": "PRTG",
    "name": "Protagonist Therapeutics, Inc.",
    "description": "Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with hematologic and other serious conditions. Founded in 2015 and headquartered in Newark, California, Protagonist is dedicated to advancing its proprietary peptide-based therapeutics platform, which leverages the body's natural processes to develop new treatments. The company is primarily known for its lead product candidate, PTG-300, an investigational therapy for the treatment of polycythemia vera, a serious blood disorder. Protagonist's innovative approach aims to address unmet medical needs in various areas, including oncology and autoimmune diseases, by harnessing the power of peptides that mimic and modulate biological pathways. The company\u2019s robust pipeline includes several other candidates targeting various conditions, showcasing its commitment to improving patient outcomes. Protagonist Therapeutics is driven by a mission to provide transformative therapies that enhance the quality of life for individuals suffering from debilitating diseases, supported by a strong team of scientific and clinical experts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Newark, California, USA",
    "founded": "2015",
    "website": "https://www.protagonist-inc.com",
    "ceo": "Dinesh V. Patel",
    "social_media": {
        "twitter": "https://twitter.com/ProtagonistTx",
        "linkedin": "https://www.linkedin.com/company/protagonist-therapeutics/"
    },
    "investor_relations": "https://investors.protagonist-inc.com",
    "key_executives": [
        {
            "name": "Dinesh V. Patel",
            "position": "CEO"
        },
        {
            "name": "Michael W. DeMarco",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PTG-300",
                "PTG-100",
                "PTG-200"
            ]
        }
    ],
    "seo": {
        "meta_title": "Protagonist Therapeutics, Inc. | Innovative Peptide-Based Therapeutics",
        "meta_description": "Learn about Protagonist Therapeutics, Inc., a biopharmaceutical company developing novel peptide-based therapies for serious conditions. Discover our pipeline and commitment to patient care.",
        "keywords": [
            "Protagonist Therapeutics",
            "Biotechnology",
            "Pharmaceuticals",
            "PTG-300",
            "Polycythemia Vera",
            "Peptide Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Protagonist Therapeutics specialize in?",
            "answer": "Protagonist Therapeutics specializes in developing peptide-based therapeutics for hematologic and other serious conditions."
        },
        {
            "question": "Who is the CEO of Protagonist Therapeutics?",
            "answer": "Dinesh V. Patel is the CEO of Protagonist Therapeutics, Inc."
        },
        {
            "question": "Where is Protagonist Therapeutics headquartered?",
            "answer": "Protagonist Therapeutics is headquartered in Newark, California, USA."
        },
        {
            "question": "What are Protagonist's lead product candidates?",
            "answer": "Protagonist's lead product candidates include PTG-300, PTG-100, and PTG-200."
        },
        {
            "question": "When was Protagonist Therapeutics founded?",
            "answer": "Protagonist Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "GILD"
    ]
}